{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:50:20Z","timestamp":1794473420735,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2B5B01002360"],"award-info":[{"award-number":["NRF-2021R1A2B5B01002360"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91739-w","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:23:06Z","timestamp":1740802986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Secondary prevention with antiplatelet medications in patients with antiphospholipid antibody-related stroke"],"prefix":"10.1038","volume":"15","author":[{"given":"Wookjin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung-Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Yeong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Hwa","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"91739_CR1","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"R Cervera","year":"2002","unstructured":"Cervera, R. et al. Antiphospholipid syndrome: clinical and Immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 46, 1019\u20131027 (2002).","journal-title":"Arthritis Rheum."},{"key":"91739_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/0961203312446974","volume":"21","author":"MT Bertero","year":"2012","unstructured":"Bertero, M. T. et al. Antiphospholipid syndrome in Northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. Lupus 21, 806\u2013809 (2012).","journal-title":"Lupus"},{"key":"91739_CR3","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.3346\/jkms.2020.35.e35","volume":"35","author":"JJ Hwang","year":"2020","unstructured":"Hwang, J. J. et al. Epidemiology of antiphospholipid syndrome in Korea: a nationwide population-based study. J. Korean Med. Sci. 35, e35 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"91739_CR4","doi-asserted-by":"crossref","unstructured":"Kleindorfer, D. O. et al. guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association\/American Stroke Association. Stroke 52, e364\u2013e467 (2021).","DOI":"10.1161\/STR.0000000000000375"},{"key":"91739_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo, V. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132, 1365\u20131371 (2018).","journal-title":"Blood"},{"key":"91739_CR6","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","volume":"6","author":"SC Woller","year":"2022","unstructured":"Woller, S. C. et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv. 6, 1661\u20131670 (2022).","journal-title":"Blood Adv."},{"key":"91739_CR7","first-page":"15","volume":"7","author":"H Okuma","year":"2009","unstructured":"Okuma, H., Kitagawa, Y., Yasuda, T., Tokuoka, K. & Takagi, S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int. J. Med. Sci. 7, 15\u201318 (2009).","journal-title":"Int. J. Med. Sci."},{"key":"91739_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou, M. G. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 78, 1296\u20131304 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"91739_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","volume":"157","author":"D Keeling","year":"2012","unstructured":"Keeling, D. et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br. J. Haematol. 157, 47\u201358 (2012).","journal-title":"Br. J. Haematol."},{"key":"91739_CR10","unstructured":"Intercollegiate Stroke Working Party & Royal College of Physicians. National Clinical Guideline for Stroke, 2023 Edition. https:\/\/www.strokeguideline.org\/app\/uploads\/2023\/04\/National-Clinical-Guideline-for-Stroke-2023.pdf (2023)."},{"key":"91739_CR11","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1177\/0961203320950461","volume":"29","author":"H Cohen","year":"2020","unstructured":"Cohen, H. et al. 16th international Congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Lupus 29, 1571\u20131593 (2020).","journal-title":"Lupus"},{"key":"91739_CR12","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1161\/01.STR.29.11.2245","volume":"29","author":"P Verro","year":"1998","unstructured":"Verro, P., Levine, S. R. & Tietjen, G. E. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 29, 2245\u20132253 (1998).","journal-title":"Stroke"},{"key":"91739_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","volume":"117","author":"MH Rosove","year":"1992","unstructured":"Rosove, M. H. & Brewer, P. M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann. Intern. Med. 117, 303\u2013308 (1992).","journal-title":"Ann. Intern. Med."},{"key":"91739_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJM199504133321504","volume":"332","author":"MA Khamashta","year":"1995","unstructured":"Khamashta, M. A. et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332, 993\u2013997 (1995).","journal-title":"N. Engl. J. Med."},{"key":"91739_CR15","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/archinte.1997.00440390101013","volume":"157","author":"S Krnic-Barrie","year":"1997","unstructured":"Krnic-Barrie, S., O\u2019Connor, C. R., Looney, S. W., Pierangeli, S. S. & Harris, E. N. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch. Intern. Med. 157, 2101\u20132108 (1997).","journal-title":"Arch. Intern. Med."},{"key":"91739_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jama.291.5.576","volume":"291","author":"SR Levine","year":"2004","unstructured":"Levine, S. R. et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291, 576\u2013584 (2004).","journal-title":"JAMA"},{"key":"91739_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/rheumatology\/key340","volume":"58","author":"N Ohnishi","year":"2019","unstructured":"Ohnishi, N. et al. Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome. Rheumatology (Oxford) 58, 969\u2013974 (2019).","journal-title":"Rheumatology (Oxford)"},{"key":"91739_CR18","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","volume":"129","author":"C van Walraven","year":"2006","unstructured":"van Walraven, C., Jennings, A., Oake, N., Fergusson, D. & Forster, A. J. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 129, 1155\u20131166 (2006).","journal-title":"Chest"},{"key":"91739_CR19","doi-asserted-by":"publisher","first-page":"11686","DOI":"10.1038\/s41598-022-16019-3","volume":"12","author":"W Yang","year":"2022","unstructured":"Yang, W., Kang, D. W., Kim, J. M., Jung, K. H. & Lee, S. H. Neuroimaging features of antiphospholipid antibody-related stroke compared with atrial fibrillation-related stroke. Sci. Rep. 12, 11686 (2022).","journal-title":"Sci. Rep."},{"key":"91739_CR20","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1111\/jth.15047","volume":"18","author":"KMJ Devreese","year":"2020","unstructured":"Devreese, K. M. J. et al. Guidance from the scientific and standardization committee for lupus anticoagulant\/antiphospholipid antibodies of the international society on thrombosis and haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J. Thromb. Haemost. 18, 2828\u20132839 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"91739_CR21","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1111\/jth.12732","volume":"12","author":"P Fontana","year":"2014","unstructured":"Fontana, P., Poncet, A., Lindhoff-Last, E., de Moerloose, P. & Devreese, K. M. Refinement of the cutoff values of the hemosil acustar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. J. Thromb. Haemost. 12, 2034\u20132037 (2014).","journal-title":"J. Thromb. Haemost."},{"key":"91739_CR22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/j.1538-7836.2010.03857.x","volume":"8","author":"P de Moerloose","year":"2010","unstructured":"de Moerloose, P., Reber, G., Musial, J. & Arnout, J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J. Thromb. Haemost. 8, 1540\u20131546 (2010).","journal-title":"J. Thromb. Haemost."},{"key":"91739_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/MBC.0b013e32836466b5","volume":"25","author":"Y Chung","year":"2014","unstructured":"Chung, Y., Kim, J. E., Lim, H. S. & Kim, H. K. Clinical performance of anticardiolipin and antibeta2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods. Blood Coagul. Fibrinol. 25, 10\u201315 (2014).","journal-title":"Blood Coagul. Fibrinol."},{"key":"91739_CR24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/ene.15191","volume":"29","author":"W Yang","year":"2022","unstructured":"Yang, W. et al. Current status and role of antiphospholipid antibody testing in cryptogenic stroke. Eur. J. Neurol. 29, 753\u2013760 (2022).","journal-title":"Eur. J. Neurol."},{"key":"91739_CR25","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","volume":"378","author":"D Garcia","year":"2018","unstructured":"Garcia, D. & Erkan, D. Diagnosis and management of the antiphospholipid syndrome. N. Engl. J. Med. 378, 2010\u20132021 (2018).","journal-title":"N. Engl. J. Med."},{"key":"91739_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295\u2013306 (2006).","journal-title":"J. Thromb. Haemost."},{"key":"91739_CR27","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran, R. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123, 2736\u20132747 (2011).","journal-title":"Circulation"},{"key":"91739_CR28","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","volume":"376","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza, G., Crowther, M., Branch, W. & Khamashta, M. A. Antiphospholipid syndrome. Lancet 376, 1498\u20131509 (2010).","journal-title":"Lancet"},{"key":"91739_CR29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s11239-020-02155-y","volume":"50","author":"FT Arantes","year":"2020","unstructured":"Arantes, F. T. et al. Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome. J. Thromb. Thrombol. 50, 772\u2013781 (2020).","journal-title":"J. Thromb. Thrombol."},{"key":"91739_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood.2019003863","volume":"135","author":"S Chaturvedi","year":"2020","unstructured":"Chaturvedi, S. et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood 135, 239\u2013251 (2020).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91739-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91739-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91739-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T04:23:11Z","timestamp":1740802991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91739-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91739"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91739-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7282"}}